

RECEIVED
CENTRAL FAX CENTER

MAY 15 2007

REMARKS

Amendments

The Specification is amended to correct typographical errors in the description wherein the “first” and “second” marker identifiers were inadvertently reversed (see depiction in Fig. 1); claims 1, 8-14, 26 and 29 are similarly corrected. Claim 29 is amended is also amended as requested to modify the punctuation, and to expressly recite the inherent limitations that the transgene-encoded recombinase is (i) genome-incorporated, (ii) promoter-operably-linked, and (iii) site-specific. These amendments do not change the scope or subject matter of the claims and introduce no new matter.

Claim Objection

The objections are addressed by the foregoing amendments.

35USC112, first paragraph (enablement)


The enablement rejection is addressed by amending claim 29 to expressly recite the inherent limitations that the transgene-encoded recombinase is (i) genome-incorporated, (ii) promoter-operably-linked, and (iii) site-specific.

35USC112, second paragraph

The phrase “wherein presence of the recombinase in the cell promotes recombination between the target sites of the first and second chromosomes” is submitted to impose an accurate functional limitation on the claimed transgenic mouse. As noted in the Specification, the recombinase is activated to provide tissue or cell-type or developmental-stage specific expression. Hence, whether the recited recombination has occurred in a recited transgenic mouse will depend upon whether the expression of the recombinase has occurred (i.e. been activated) in that mouse, for example by activation of an inducible promoter or a developmental stage-specific promoter, etc. (see e.g. Specification p. 7, para at line 14). The claims are intended to encompass a transgenic mouse constructed as recited; hence, the same transgenic mouse does not infringe the claims only after the recombinase has been activated.

Please charge our Deposit Account No.19-0750 (order S03-250) any fees or necessary extensions of time for this communication.

Respectfully submitted,
Science & Technology Law Group



Richard Aron Osman, J.D., Ph.D., Reg. No. 36,627
Tel (949) 218-1757; Fax (949) 218-1767

"To Help Our Customers Get Patents"
Mission Statement, USPTO External Customer Services Guide